FFA
NBIX icon

Farther Finance Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Farther Finance Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422K Sell
2,503
-444
-15% -$65.9K ﹤0.01% 1680
2026
Q1 		$391K Buy
2,947
+193
+7% +$25.6K ﹤0.01% 1563
2025
Q4 		$391K Buy
2,754
+1,620
+143% +$235K ﹤0.01% 1476
2025
Q3 		$159K Buy
1,134
+215
+23% +$29.1K ﹤0.01% 1745
2025
Q2 		$116K Buy
919
+233
+34% +$26.7K ﹤0.01% 1688
2025
Q1 		$73.4K Buy
686
+193
+39% +$24.4K ﹤0.01% 1687
2024
Q4 		$67.3K Buy
493
+51
+12% +$6.31K ﹤0.01% 1502
2024
Q3 		$50.9K Hold
442
– – ﹤0.01% 1641
2024
Q2 		$61.9K Buy
442
+7
+2% +$960 ﹤0.01% 1329
2024
Q1 		$61.5K Buy
435
+5
+1% +$683 ﹤0.01% 1110
2023
Q4 		$56.7K Buy
430
+7
+2% +$806 ﹤0.01% 994
2023
Q3 		$47.6K Buy
423
+413
+4,130% +$43.5K 0.01% 789
2023
Q2 		$943 Buy
10
+5
+100% +$489 ﹤0.01% 1994
2023
Q1 		$506 Hold
5
– – ﹤0.01% 2002
2022
Q4 		$597 Buy
+5
New +$586 ﹤0.01% 1799

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farther Finance Advisors's NBIX Position: Q2 2026 in Review

Farther Finance Advisors reduced its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, selling an estimated $65.9K and leaving 2,503 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

Farther Finance Advisors first reported a position in NBIX in Q4 2022 and has held it in 15 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Farther Finance Advisors held 2,503 shares of Neurocrine Biosciences worth $422K as of Q2 2026.
  • Farther Finance Advisors sold 444 Neurocrine Biosciences shares in Q2 2026, an estimated $65.9K.
  • Neurocrine Biosciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #1680 holding.
  • Farther Finance Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 15 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.